Meeting: 2017 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9508 Citation: J Clin Oncol 35, 2017 (suppl; abstr 9508) Authors: Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, et. al. Background: Nivolumab (nivo) and the combination of nivo + ipilimumab (ipi) improve response rates (RR) and progression-free survival (PFS)...
Pro zobrazení tohoto obsahu je třeba být přihlášen.